In short
Clinical trials are studying ALXN2420 in adults with acromegaly. The main goal is to see whether it can lower IGF-1 levels when used with somatostatin analogs, and to assess its overall effect in this patient group.
Key points
- ALXN2420 is being studied in a Phase 2 trial for adults with acromegaly. The study compares ALXN2420 with placebo when used together with somatostatin analog therapy. The main goal is to see whether ALXN2420 can reduce serum IGF-1 levels after 15 weeks of treatment. The trial plans to enroll 60 participants. Its current status is suspended.
Trial overview
The available study is a Phase 2 trial of ALXN2420 in people with acromegaly, a condition being studied in adults. It is an interventional study, which means researchers assign the study treatment and compare results over time.
The trial compares ALXN2420 with placebo, which is a look-alike treatment with no active study drug, and both are given together with somatostatin analogs. The somatostatin analogs listed in the trial are octreotide acetate and lanreotide acetate.
Who can participate
This study is designed for adult participants with acromegaly. The brief summary says the treatment is being tested in adults who are already receiving somatostatin analog therapy.
The trial includes a planned enrollment of 60 participants. This number shows how many people the researchers planned to include in the study.
What is being measured
The main endpoint, or main result the study wants to measure, is the percentage change from baseline in serum IGF-1 level at Week 15. Baseline means the starting value before treatment begins, and serum IGF-1 is a blood marker used to follow disease activity in acromegaly.
The brief summary states that the purpose of the study is to evaluate whether 15 weeks of ALXN2420 treatment can lower IGF-1 levels better than placebo when used with SSA therapy. SSA therapy means treatment with somatostatin analogs.
Trial status and design
The trial status is Suspended, so the study is not actively moving forward at the time shown in the source data. The study is listed as interventional and uses a comparison between ALXN2420 and matching placebo.
Only one trial was provided in the source data, so this article focuses on that single Phase 2 study in acromegaly.